Trial
NCT05039515
A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Clementia Pharmaceuticals Inc.
Collaborators
Ipsen
Condition
Fibrodysplasia Ossificans Progressiva
Intervention
IPN60130
Why stopped
Following the planned FALKON Part A primary analysis, the study did not meet its primary endpoint of reducing heterotopic ossification (HO) volume compared with placebo and met predefined futility criteria.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-24